Change over period: —
NSE · KILITCH
KILITCH DRUG
-11.7% from the 52-week high · +84.9% above the low
Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products portfolio includes Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. Its Parenteral and Nasal Products has a range of products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostic, uterine stimulants, veterinary and many other areas in the form of ampoules and vials. The Company’s range of oral formulations includes tablets, capsules, dry syrups and oral powders. The Company’s medical devices offer a C-Seal brand. The company has a range of cosmetics ranging from oil, lotion and liquid to cream and paste in skin care, personal care, and hair care category. The firm has its manufacturing units located in India and Ethiopia.
The short version. KILITCH DRUG reported revenue of ₹50 crore for Sep 2026, up 2.0% from a year earlier. Net profit was ₹2 crore (down 75.0% year on year). Return on equity was 10.8% in Mar 2026. Promoter holding was 63.77% in Sep 2026, down 5.46 points over 8 quarters.
1 · The price
How has the stock traded?
KILITCH DRUG trades 11.7% below its 52-week high and 84.9% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹50 cr.
Sep 2026 net profit of ₹2 cr.
12.3 pts lower than a year earlier.
Revenue compounded at 20.1% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50 | 45 | 90 | 54 | 49 | 43 | 61 | 56 |
| Net profit | 2 | 3 | 15 | 4 | 8 | 3 | 10 | 6 |
| Net margin % | 4.4 | 6.5 | 16.2 | 8.2 | 16.7 | 7.0 | 17.0 | 10.6 |
| EPS (₹) | 0.64 | 0.83 | 4.15 | 1.27 | 2.34 | 0.87 | 2.97 | 1.7 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 235 | 198 | 154 | 140 | 114 | 69 | 53 | 82 |
| Net profit | 30 | 27 | 15 | 10 | 7 | 4 | 1 | 4 |
| Net margin % | 12.8 | 13.5 | 9.5 | 7.5 | 6.4 | 5.4 | 1.6 | 4.6 |
| EPS (₹) | 8.63 | 7.64 | 4.18 | 3.08 | 2.17 | 1.09 | 0.25 | 1.15 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 10.8% in Mar 2026; debt to equity is 0.32.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 10.8 | 13.2 | 8.3 | 6.9 |
| Return on capital % | 13.2 | 17.3 | 14.4 | 11.2 |
| EBITDA margin % | 19.4 | 20.3 | 18.0 | 14.4 |
| Net margin % | 12.2 | 12.8 | 9.2 | 7.3 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 20.1% | 28.2% |
| Profit CAGR | 42.4% | 52.4% |
4 · The owners
Who holds it, and are they adding?
Down 5.46 pts over 8 quarters.
Up 0.11 pts over 8 quarters.
Up 0.5 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.23 | 69.23 | 69.23 | 63.77 | 63.77 | 63.77 | 63.77 | 63.77 | -5.46 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0.12 | 0.11 | +0.11 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | +0.5 |
| Public | 30.77 | 30.77 | 30.76 | 36.23 | 36.23 | 36.22 | 36.11 | 35.62 | +4.85 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.01% of NAV
- Bandhan BSE Healthcare Index Fund0.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for KILITCH DRUG are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about KILITCH DRUG
What is the KILITCH DRUG share price?
KILITCH DRUG (KILITCH) last closed at ₹234.00, up 1.69% on the day. Its 52-week range is ₹124.45 to ₹260.70.
What is the market cap of KILITCH DRUG?
KILITCH DRUG has a market capitalisation of about ₹807 crore. Its price-to-earnings ratio is 33.6.
How are KILITCH DRUG's latest results?
KILITCH DRUG reported revenue of ₹50 crore for Sep 2026, up 2.0% from a year earlier. Net profit was ₹2 crore (down 75.0% year on year). Return on equity was 10.8% in Mar 2026. Promoter holding was 63.77% in Sep 2026, down 5.46 points over 8 quarters.
Who owns KILITCH DRUG?
As of Sep 2026, shareholding was: Promoter 63.77%, FII 0.11%, DII 0.5%, Public 35.62%.
How many mutual funds hold KILITCH DRUG?
2 mutual fund schemes held KILITCH DRUG in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 24 Mar 2026 · Bonus issue 1:1
- 15 Jul 2025 · Rights issue 2:23
- 20 Sep 2019 · Final Dividend - Rs. 0.5
- 18 Sep 2018 · Final Dividend - Rs. 0.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.